Pre-Conference Workshop Day

Tuesday 5th December 2023

9:00 – 12:00 pm
Workshop A

Targets 101: Outlining the Current ADC Target Landscape

  • Robert Lutz Chief Scientific Officer, Iksuda Therapeutics
  • Jutta Deckert Executive Director - Translational, Research & Development, Iksuda Therapeutics


This session will allow you to gain detailed knowledge of the current antibody-drug conjugate target landscape, covering both highly saturated clinically validated targets, to more novel explorations. This will provide you with key insights to determine your next ADC target for development.

Join this workshop to get an up-to-date understanding of the current target landscape, from successes and failings of clinically validated targets, to the most interesting advancements in novel targets to influence your pipeline strategy.

The highlights of this workshop include:

  • Survey the current clinically validated and novel target landscape for ADCs
  • Exploring novel indications and targets outside of the norm
  • What will be the next HER2?

12:00 pm Networking Lunch Session

1:00- 4:00 pm
Workshop B

Harnessing Target Specificity With Novel ADC Technology Advancements to Minimize Off-Target Toxicity


This workshop will be your opportunity to discover a range of novel ADC technology advancements in development to progress target specificity and widen therapeutic windows. This is an unmissable chance to participate in deepdive discussions into everything from bispecific targets, to novel linker-payload technologies.

Join this workshop to gain a bigger picture on linker-payloads to supplement your technology selection for your ADC development to best compliment your target selection and ensure successful progression into the clinic.

The highlights of this workshop include:

  • Discovering how your target effects the safety profile of your ADC, and how precision antibody technology can help with this
  • Highlighting unique approaches to target selection when working with bispecific antibodies
  • Unveiling novel linker-payload technologies to better saturate target cell surface antigens with minimal toxicities